Skip to main content
. Author manuscript; available in PMC: 2009 Jun 9.
Published in final edited form as: Exp Cell Res. 2008 Mar 20;314(10):2110–2122. doi: 10.1016/j.yexcr.2008.03.008

Figure 4. In vivo studies.

Figure 4

(A) Representative H&E-stained sections of brain tumors derived from orthotopic implantation of GL-261 glioma cells in adherence (right panels) or as spheroids in serum-free medium (left panels). Arrows, areas of tumor infiltration into the brain parenchyma. (B) In vivo growth of GL-261, U87Mg, FEMX-1 and MA-11 cells in adherence (adh) or as spheroids (sph). GL-261 and U87Mg cells were orthotopically implanted into C57Bl/6 and nu/nu mice, respectively; the percentage of mice (6/cohort) developing an intracranial tumor > 1mm3 after 20 days was calculated. Human FEMX-1 melanoma and MA-11 breast carcinoma cells were implanted s.c. into the right flank of nu/nu mice; the percentage of mice (6/cohort) developing a tumor > 500 mm3 after 30 days (FEMX-1) and 70 days (MA-11) was calculated.